Malaria transmission-blocking vaccines – ARTES and Burnet announced a development project
ARTES Biotechnology and Burnet Institute have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria Vaccine Initiative (MVI).
The project will use exciting novel technology developed at the Burnet Institute. ARTES holds the international patent rights and adapted the platform to vaccine production (known as the Metavax® platform).
Purified vaccine antigens (Pfs25 and Pfs230) will be produced as virus-like particles (VLPs, a type of nano-particle) for testing in laboratory studies. The VLPs will be taken up by immune cells to prime and prepare the immune system to fight malaria.
The project will focus on strategies to produce vaccines that can block the transmission of malaria infection from mosquitoes to people, as part of a program funded by MVI.
